Rofecoxib, Merck, and the FDA.
Kim
Peter S
PS
Reicin
Alise S
AS
D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000266:history; D017277:Drug Approval / Q000266:history*; D004345:Drug Industry / Q000266:history*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000266:history; D016032:Randomized Controlled Trials as Topic / Q000266:history; D013450:Sulfones / Q000009:adverse effects* / Q000266:history; D014481:United States; D014486:United States Food and Drug Administration
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib